CompanyGraph
Guangdong Taienkang Pharmaceutical Co., Ltd.
301263 · SZSE · China
tai-kang.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.17B, above the global median of $1.14B
- FinancialsAltman Z-Score 7.73: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.45%Below 5Y avg (0.85%)
Annual Rate
CNY 0.08Paid semi-annual
Payout Ratio
285.7%High
Payback Period
78.2 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.82BCNY1.17B · vs all stocks (USD)
Revenue (TTM)
648.09MCNY97.05M · vs all stocks (USD)
Profit Margin
-0.73%Beta
0.2920xvs all stocks
52-Week Change
-29.19%vs all stocks
Forward Annual Dividend Yield
0.45%vs all stocks
Market Capitalization
7.82BCNY1.17B · vs all stocks (USD)
Enterprise Value
9.53BCNY1.43B · vs all stocks (USD)
Forward P/E
23.30xPrice to Sales (TTM)
12.17xPrice to Book (MRQ)
5.94xEnterprise to Revenue
14.70xGross Margin
46.36%Profit Margin
-0.73%Operating Margin
-39.02%Return on Assets (TTM)
-1.05%Return on Equity (TTM)
-1.31%Revenue (TTM)
648.09MCNY97.05M · vs all stocks (USD)
Revenue per Share (TTM)
1.32CNYUpdated Oct 21, 2026Quarterly Revenue Growth
-19.50%Gross Profit (TTM)
345.09MCNY51.67M · vs all stocks (USD)
EBITDA (TTM)
77.39MCNY11.59M · vs all stocks (USD)
Net Income (TTM)
-4.73MCNY-708.53K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-19.49%Operating Cash Flow (TTM)
81.77MCNY12.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
52.04MCNY7.79M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0833CNYUpdated Oct 21, 2026Forward Annual Dividend Yield
0.45%vs all stocks
Trailing Annual Dividend Rate
0.2417CNYUpdated Oct 21, 2026Trailing Annual Dividend Yield
1.31%vs all stocks
5-Year Average Dividend Yield
0.85%vs all stocks
Payout Ratio
285.72%Minority Interest (Equity)
69.95MCNYFY2025 · Dec 31, 2025Revenue
674.90MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
310.07MCNYFY2025 · Dec 31, 2025Gross Profit
364.83MCNYFY2025 · Dec 31, 2025Operating Income
13.14MCNY1.97M · vs all stocks (USD)
Pre-tax Income
-8.17MCNYFY2025 · Dec 31, 2025Income Tax Expense
-20.92MCNYFY2025 · Dec 31, 2025Net Income
12.75MCNYFY2025 · Dec 31, 2025EBIT
4.46MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
77.39MCNYFY2025 · Dec 31, 2025Research & Development
77.68MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
146.20MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.23MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.63MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0583CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0583CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
490.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
490.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
12.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
15.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-48.72MCNYFY2025 · Dec 31, 2025Free Cash Flow
-156.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
579.06MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
12.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
13.45MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.98MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.92MCNYFY2025 · Dec 31, 2025Capital Expenditures
-108.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-280.00MCNYFY2025 · Dec 31, 2025Sale of Investments
363.87MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-24.39MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
480.58MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-363.67MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-93.58MCNYFY2025 · Dec 31, 2025Other Financing Charges
52.92MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
76.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
510.60MSharesUpdated Oct 21, 2026Float Shares
325.94MSharesUpdated Oct 21, 2026% Held by Insiders
49.02%vs all stocks
% Held by Institutions
2.67%vs all stocks
Total Cash (MRQ)
643.40MCNY96.34M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.22CNYUpdated Oct 21, 2026Total Debt (MRQ)
397.14MCNY59.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2315xCurrent Ratio (MRQ)
1.68xBook Value per Share (MRQ)
3.12CNYUpdated Oct 21, 2026Total Assets
2.42BCNY361.96M · vs all stocks (USD)
Total Current Assets
1.13BCNYFY2025 · Dec 31, 2025Total Liabilities
676.07MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.28BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
174.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
501.41MCNYFY2025 · Dec 31, 2025Cash
579.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
674.30KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
579.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
40.20MCNYFY2025 · Dec 31, 2025Accounts Receivable
321.06MCNYFY2025 · Dec 31, 2025Inventory
98.81MCNYFY2025 · Dec 31, 2025Accounts Payable
172.51MCNYFY2025 · Dec 31, 2025Short-term Debt
280.11MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.62MCNYFY2025 · Dec 31, 2025Long-term Debt
81.48MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
61.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
425.50MCNYFY2025 · Dec 31, 2025Retained Earnings
327.17MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.74BCNY260.73M · vs all stocks (USD)
Treasury Stock
39.00MCNYFY2025 · Dec 31, 202552-Week Low
17.52CNYUpdated Oct 21, 202652-Week High
29.77CNYUpdated Oct 21, 202652-Week Change
-29.19%vs all stocks
Beta
0.2920xvs all stocks
50-Day MA
19.48CNYUpdated Oct 21, 2026200-Day MA
21.99CNYUpdated Oct 21, 2026Avg 10-Day Volume
3.99MSharesUpdated Oct 21, 2026Avg 30-Day Volume
4.51MSharesUpdated Oct 21, 2026Diluted EPS (TTM)
-0.0100CNYUpdated Oct 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.46Profit Margin: -0.01
Financial Health
Altman Z-Score 7.73: safe zoneNotable
Altman Z-Score: 7.73
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.17B, above the global median of $1.14BNotable
Market cap (USD): 1,171,063,240.047Global Median: 1,138,450,684.034
Companies that share the same coordination system — how they create, deliver, or capture value.
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Fushine Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule